31 results about "Single tumor" patented technology

Here the inventors describe a tumor classifier based on protein expression. Also disclosed is the use of proteomics to construct a highly accurate artificial neural network (ANN)-based classifier for the detection of an individual tumor type, as well as distinguishing between six common tumor types in an unknown primary diagnosis setting. Discriminating sets of proteins are also identified and are used as biomarkers for six carcinomas. A leave-one-out cross validation (LOOCV) method was used to test the ability of the constructed network to predict the single held out sample from each iteration with a maximum predictive accuracy of 87% and an average predictive accuracy of 82% over the range of proteins chosen for its construction.

The invention relates to a method for performing prognosis condition grouping on a hepatocellular carcinoma patient who has single tumor and is about to be subjected to or is already subjected to orthotopic liver transplantation. The method comprises the steps of (1) obtaining a sample from general samples after transhepatic biopsy before transplantation or liver transplantation, and detecting CK19 and GPC3 expression conditions of tumor cells in the hepatocellular carcinoma tissue sample of the patient; (2) detecting and recording a maximum diameter of the tumor of the patient; (3) detecting and recording a serum alpha-fetoprotein level of the patient; and (4) based on a pathological section, observing whether microvascular invasion exists or not. Recurrent risks are scored according to beta coefficients of four factors in COX regression analysis; scores in items are subjected to addition; a recurrent risk group with a total score less than or equal to 4 is determined as a low recurrent risk group; a recurrent risk group with a total score equal to 5-7 is determined as a medium recurrent risk group; and a current risk group with a total score more than or equal to 8 is determined as a high recurrent risk group. Through the method, an effective auxiliary information value can be provided for a doctor and the patient; and tumor recurrence or transfer is closely monitored, so that health conditions can be discovered within the shortest time, the doctor and the patient are effectively prompted, and people are reminded to timely examine body conditions.

The invention relates to a method and equipment for detecting tumor microsomes, and especially relates to and discloses a method and a detector for detecting tumor microsomes by using laser tweezers and micro fluidics. The detection method comprises the steps that: laser tweezers of different polarizations are generated; dual-beam double laser tweezers are used for focusing, and particles combined with tumor microsome antibodies in a channel of a micro fluidic chip are captured by the tweezers; a sample to be detected is mixed with the particles combined with tumour microsome antibodies; changes of physical parameters of the particles combined with tumor microsome antibodies before and after being mixed with the sample are collected by the detector, and qualification and accurate quantitation of the sample requiring detection can be carried out according to the parameters. The detector comprises a laser system, a nanometer positioning system, a camera system, optical parts, mechanical parts, a data collecting and transmitting system, and automatic controlling and image processing application software. According to the invention, single tumor microsome particle can be detected, and the method and the equipment are characterized in high specificity, simple operation, short detection period, high sensitivity, and good repeatability. Also, with the method and the equipment, blood samples can be re-detected.

The use of genomic tests shows variability between the primary tumor and the metastases in most circumstances referred to as tumor heterogeneity. Since it is unduly invasive and difficult to obtain samples from the primary and metastatic tumors within a patient, a need exists for a method of testing chemotherapeutic effectiveness in a patient that is applicable to both primary tumor and metastases. Provided are methods of using the MiCK assay to determine the most effective drug candidate(s) for an individual patient by testing a single tumor site. In a further embodiment, the kinetic unit (KU) value obtained by analysis of cancer cells from a tumor site in an individual patient in the presence of a drug candidate is within two standard deviations of the KU value obtained by analysis of a different tumor site in the patient in the presence of the same drug candidate.

The invention relates to the technical field of microsatellite site detection, in particular to a method and system for detecting the instability state of a microsatellite; and the method comprises the following steps: carrying out DNA extraction, fragmentation treatment, terminal repair and joint connection on a cancerous tissue sample; carrying out amplification, hybridization, capture, PCR amplification and purification to obtain a sequencing library; and obtaining targeted capture sequencing data of a tumor tissue sample through second-generation computer sequencing, and carrying out information analysis related to microsatellite instability state detection according to an MSI model. Compared with the prior art, the genetic information of the tumor tissue of the testee is obtained by adopting the current mature next-generation sequencing technology, single tumor tissue analysis can be carried out, dependence on a control sample is avoided, the limitation of microsatellite detectionis broken through, the method can be suitable for multiple gene combinations, an MSI site probe does not need to be specially designed, and the applicability is high; moreover, the detection cost canbe saved, the method is efficient, systematic, economic, simple and convenient, and the detection sensitivity is improved.

The present invention relates to the technical field of detection of microsatellite sites, in particular to a method and system for detecting instability of microsatellites. DNA is extracted from cancerous tissue samples, fragmented, end repaired, and jointed; and then amplified , hybridization, capture, PCR amplification, and purification to obtain a sequencing library; obtain targeted capture sequencing data of tumor tissue samples through second-generation sequencing, and analyze information related to microsatellite instability detection based on the MSI model. Compared with the existing technology, the present invention adopts the current mature next-generation sequencing technology to obtain the genetic information of the tumor tissue of the test subject, can analyze a single tumor tissue, does not rely on control samples, breaks the limitation of microsatellite detection, and is applicable Based on the combination of multiple genes, there is no need to specially design MSI site probes, the applicability is strong, and the detection cost can be saved. It is efficient, systematic, economical and simple, and improves the sensitivity of detection.

The use of genomic tests shows variability between the primary tumor and the metastases in most circumstances referred to as tumor heterogeneity. Since it is unduly invasive and difficult to obtain samples from the primary and metastatic tumors within a patient, a need exists for a method of testing chemotherapeutic effectiveness in a patient that is applicable to both primary tumor and metastases. Provided are methods of using the MiCK assay to determine the most effective drug candidate(s) for an individual patient by testing a single tumor site. In a further embodiment, the kinetic unit (KU) value obtained by analysis of cancer cells from a tumor site in an individual patient in the presence of a drug candidate is within two standard deviations of the KU value obtained by analysis of a different tumor site in the patient in the presence of the same drug candidate.

The invention belongs to the technical field of chip detection and particularly discloses an antibody chip kit for detecting early gastric cancer. The antibody chip kit is characterized in that various gastric cancer marker related antibodies are fixed onto a solid-phase carrier, and the specific antibodies are screened from 35 routine gastric cancer marker related antibodies. The antibody chip kit can detect a plurality of gastric cancer related antigen proteins at the same time, and the detection effect of a combined antibody chip is better than that of single tumor markers.

The present invention provides a tumor cell content assessment method, device, system and computer-readable medium capable of improving the accuracy of tumor cell content assessment, wherein the tumor cell content assessment method includes the following steps: obtaining one by one the tumor cells that meet the predetermined mutation condition The average sample mutation frequency and control mutation frequency of the mutation site, and calculate the content of individual tumor cells corresponding to the mutation site; once the content of all individual tumor cells corresponding to all mutation sites that meet the predetermined mutation conditions are obtained, the calculating the content of all individual tumor cells to obtain the content of tumor cells in the test sample; evaluating the calculated content of tumor cells in the test sample according to a predetermined evaluation rule to obtain the content of tumor cells in the test sample after evaluation.

The invention belongs to the technical field of copy number variation detection, and discloses a method for detecting copy number variation and deletion types based on a single tumor sample, and a computer to establish a dynamic balance mechanism for copy number expansion and copy number deletion range, and to continuously correct the number of reads during the iterative detection process The benchmark, correct the parameters of the statistical test distribution, objectively detect significant copy number variation and weakly significant copy number variation; build a Bayesian inference model, and correctly detect the copy number variation status and copy number deletion type. The invention correctly detects the state of copy number variation and the type of copy number deletion, and provides the information of heterozygote deletion and homologous deletion. Considering the comparison quality and errors, the invention rationally corrects the GC content of the whole genome; establishes a dynamic balance mechanism of copy number expansion and copy number deletion range to accurately locate the copy number benchmark and accurately detect the variation state of the copy number.

The invention relates to an inhibitory synthetic Notch and dual-target system and its preparation method and application, which comprises a fusion protein combining Notch1 sequence and CSK kinase. Using the inhibitory synthetic Notch to obtain a dual-target system can simultaneously target two tumor-associated antigens, improve the accuracy of T cells in killing tumor cells, and effectively overcome the off-target toxicity caused by targeting a single tumor-associated antigen.

The invention discloses a composition and immune cells for enhancing T lymphocyte immunity and application. The composition of the present invention comprises the following components (a) to (d): (a)interleukin-15, a mutant thereof or a functional fragment thereof, or an encoding nucleic acid thereof; (b) interleukin-15 receptor alpha, a mutant or a functional fragment thereof, or an encoding nucleic acid thereof; (c) interleukin-12, a mutant or a functional fragment thereof, or an encoding nucleic acid thereof; and (d) a PD1-CD80 fusion protein, a mutant or a functional fragment thereof, oran encoding nucleic acid thereof. The composition, the immune cells and the method for improving the properties of the T lymphocytes can all excite stronger immune response, and induce tumor specificCD4 and CD8T cells in a higher proportion, so that the defects of tumor immunosuppression and non-ideal clinical effect which are difficult to solve by a single tumor treatment means are expected to be overcome.